Product Information
CYTOMEL 5 MCG TABLET is a brand product labeled by Pfizer Inc., priced at $0.3857 per EA under NDC 60793011501. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the liothyronine sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 ug/1
Manufacturer
Pfizer Inc.NDC
60793011501
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LIOTHYRONINE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA010379FDA Approved
Before 1982
TE Code
AB
On Market Since
5/8/1956
Pharmacological Classes
Price Statistics
The NADAC for CYTOMEL 5 MCG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 59.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3857 per EA |
|---|---|
| All-time high | $1.9483 (Nov 15, 2023) |
| All-time low | $0.3679 (Dec 17, 2025) |
| 52-week high | $0.3865 |
| 52-week low | $0.3679 |
| Median price | $1.6788 |
| Average price | $1.3469 |
| Largest weekly change | -81.0% (Dec 6, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 48% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Pfizer Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
liothyronine sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
l-Triiodothyronine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CYTOMEL 5 MCG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CYTOMEL 5 MCG TABLET, manufactured by Pfizer Inc., is $0.3857 per EA (NDC 60793011501), effective Sep 30, 2026.
How has the price of CYTOMEL 5 MCG TABLET changed over time?
Over the history we have for it, the NADAC for CYTOMEL 5 MCG TABLET has declined 59.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CYTOMEL 5 MCG TABLET?
Since Nov 28, 2013, the NADAC for CYTOMEL 5 MCG TABLET has ranged from a low of $0.3679 (Dec 17, 2025) to a high of $1.9483 (Nov 15, 2023), with a median of $1.6788 per EA.
Are there cheaper alternatives to CYTOMEL 5 MCG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIOTHYRONINE SOD 5 MCG TAB, is $0.2023 per EA — about 48% below CYTOMEL 5 MCG TABLET.
Who manufactures CYTOMEL 5 MCG TABLET?
CYTOMEL 5 MCG TABLET (NDC 60793011501) is labeled by Pfizer Inc., and CMS classifies it as a brand product.